Encyclopedia of Heart Diseases

2011 Edition
| Editors: M. Gabriel Khan

Arrhythmias

Reference work entry
DOI: https://doi.org/10.1007/978-1-60761-219-3_17

Overview

Arrhythmia is the term used for an irregularity or rapidity of the heartbeat or an abnormal heart rhythm. The patient experiences  palpitations, the sensation as stronger, more forceful, or rapid heartbeats, or skipping of beats.

The sinus node, a very small group of specialized cells, is located in the upper right corner of the heart (see Fig. 1a). The node is about 30 × 3 mm thick. Through its genetic code and the influx and efflux of sodium and potassium into its cells, this natural pacemaker spontaneously fires infinitesimal electrical discharges that are conducted through electric cable-like bundles to the atria and ventricles causing the heart muscle to contract about 70 times a minute.
This is a preview of subscription content, log in to check access.

Bibliography

References

  1. Alboni P, Tomasi C, Menozzi C et al (2001) Efficacy and safety of out-of-hospital self-administered single dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol 37:548–553PubMedGoogle Scholar
  2. Atié J, Bragada P, Bragada J et al (1990) Clinical and electrophysiologic characteristics of patients with antidromic circus movement tachycardia in the Wolff-Parkinson-White syndrome. Am J Cardiol 66:1082PubMedGoogle Scholar
  3. Ben-David J, Zipes DP (1993) Torsades de pointes and proarrhythmia. Lancet 341:1578PubMedGoogle Scholar
  4. Benditt DG, Dunnigan A, Buetikofer J et al (1991) Flecainide acetate for long-term prevention of PSVT. Circulation 83:345PubMedGoogle Scholar
  5. Bigger JT (1983) Definition of benign versus malignant ventricular arrhythmias: targets for treatment. Am J Cardiol 52:47CPubMedGoogle Scholar
  6. Boydak B, Nalbantgil S, Fici F et al (2005) A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Investig 25:409–416PubMedGoogle Scholar
  7. Brixius K, Middeke M, Lichtenthal A et al (2007) Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 34:327–331. [Web of Science][Medline]PubMedGoogle Scholar
  8. Buxton AE, Marchlinski FE, Flores BT et al (1986) Non-sustained ventricular tachycardia in patients with coronary artery disease: role of electro-physiological study. Circulation 75:1178Google Scholar
  9. Callans DJ (2008) Comparing antiarrhythmic drugs and catheter ablation for treatment of atrial fibrillation; apples and oranges 2008. Circulation 118:2488–2490PubMedGoogle Scholar
  10. Camm J (2010) A phase III prospective randomized double-blind active controlled, multicenter superiority study of vernakalant injection versus intravenous amiodarone in subjects with recent onset atrial fibrillation. Arrhythmias. The AVRO trial, Heart Rhythm 2010. AVROGoogle Scholar
  11. CAST Investigators (Cardiac Arrhythmia Suppression Trial) (1989) Preliminary report Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406, CASTGoogle Scholar
  12. Chou TC (1996) Electrocardiography in clinical practice, 4th edn. WB Saunders, Philadelphia, PAGoogle Scholar
  13. FDA Drug Safety Communication – 03/19/2010Google Scholar
  14. Grace AA, Camm AJ (1998) Drug therapy. Quinidine N Engl J Med 338:35Google Scholar
  15. Horowitz LN, Greenspan AM, Spielman SR et al (1985) Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 55:367PubMedGoogle Scholar
  16. Jaïs P, Cauchemez B, Macle L et al (2008) Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118:2498–2505PubMedGoogle Scholar
  17. Kerin NZ, Blevins RD, Frumin H et al (1985) Intravenous and oral loading versus oral loading alone with amiodarone for chronic refractory ventricular arrhythmias. Am J Cardiol 55:89PubMedGoogle Scholar
  18. Khan M Gabriel (1997) Cardiovascular system pharmacology. In: Dulbecco R (ed) Encylopedia of human biology, 2nd edn. Academic, San DiegoGoogle Scholar
  19. Khan M Gabriel (2007) Arrhythmias. In: Cardiac drug therapy, 7th edn. Humana/Springer, New York, pp 249–264Google Scholar
  20. Khan M Gabriel (2008) Rapid ECG interpretation, 3rd edn. Humana Springer, New York, 249–296Google Scholar
  21. Khand AU, Rankin AC, Martin W et al (2003) Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42:1944–1951PubMedGoogle Scholar
  22. Kubac G, Klinke WP, Grace M (1988) Randomized double blind trial ring sotalol and propranolol in chronic ventricular arrhythmia. Can J Cardiol 4:355PubMedGoogle Scholar
  23. Lazzara R (1989) Amiodarone and torsades de pointes. Ann Intern Med 111:549PubMedGoogle Scholar
  24. Leenhardt A, Glasser E, Burguera M et al (1994) Short-coupled variant of torsade depointes: a new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation 89:206PubMedGoogle Scholar
  25. Ludmer PL, McGowan NE, Antman EM et al (1987) Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long term follow-up. J Am Coll Cardiol 9:1357PubMedGoogle Scholar
  26. Marriott HJL (1988) Practical electrocardiography, 8th edn. Williams & Wilkins, Baltimore, MD, p 214Google Scholar
  27. Mason JW (1987) Drug therapy: amiodarone. N Engl J Med 316:455PubMedGoogle Scholar
  28. Mattioni TA, Zheutlin TA, Sarmiento JJ et al (1989) Amiodarone in patients with previous drug-mediated torsade de pointes. Ann Intern Med 111:574PubMedGoogle Scholar
  29. Nademanee K, McKenzie J, Kosar E et al (2004) A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Col Cardiol 43:2044–2053Google Scholar
  30. Nathan AW, Bexton RS, Hellestrand KG et al (1984) Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent. Postgrad Med J 60:155PubMedGoogle Scholar
  31. Nora M, Zipes DP (1993) Empiric use of amiodarone and sotalol. Am J Cardiol 72:62FPubMedGoogle Scholar
  32. Norris RM, Barnaby PF, Brown MA et al (1984) Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 2:883PubMedGoogle Scholar
  33. Packer D (2010) CABANA pilot study: Catheter ablation vs. antiarrhythmic drug therapy for atrial fibrillation. The ACC.10/i2 Summit, Atlanta, GA. CABANAGoogle Scholar
  34. Piccini JP, Hasselblad V, Peterson ED et al (2009) Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 54:1089–1095PubMedGoogle Scholar
  35. Poole JE, Werner JA, Brady GH et al (1986) Intolerance and ineffectiveness of mexiletine in patients with serious ventricular arrhythmias. Am Heart J 112:322PubMedGoogle Scholar
  36. Rosenbaum MB, Chiale PA, Halpern MS et al (1976) Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 38:934PubMedGoogle Scholar
  37. Rotmensch HH, Elkayam U, Frishman W (1983) Antiarrhythmic drug therapy during pregnancy. Ann Intern Med 98:487PubMedGoogle Scholar
  38. Ruskin JN (1989) The cardiac arrhythmia suppression trial (CAST). N Engl J Med 321:385Google Scholar
  39. Somberg JC (1987) Antiarrhythmic drugs: making sense of the deluge. Am Heart J 113:408PubMedGoogle Scholar
  40. Soyka LF, Wirtz C, Spangenberg RB (1990) Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 65(Suppl):74APubMedGoogle Scholar
  41. Stratmann HG, Kennedy HL (1987) Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 113:1470PubMedGoogle Scholar
  42. The GISSI-AF Investigators (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617Google Scholar
  43. Wellens JJH, Conover MB (1992) The ECG in emergency decision making. WB Saunders/Elsevier Science, PhiladelphiaGoogle Scholar
  44. Wyse DG (2009) Cardioversion of atrial fibrillation for maintenance of sinus rhythm: a road to nowhere. Circulation 120:1444–1452PubMedGoogle Scholar
  45. Yusuf S, Diener HC, Sacco RL et al for the PRoFESS Study Group (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225–1237. PRoFESSPubMedGoogle Scholar
  46. Yusuf S, Teo K, Anderson C et al for the TRANSCEND Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372:1174–1183. TRANSCENDPubMedGoogle Scholar

Suggested Reading

  1. Avezum Á, Piegas LS, Goldberg RJ et al (2008) For the GRACE investigators. magnitude and prognosis associated with ventricular arrhythmias in patients hospitalized with acute coronary syndromes (from the GRACE Registry). Am J Cardiol 102(12):1577–1582PubMedGoogle Scholar
  2. Bertaglia E, Tondo C, De Simone A et al (2010) Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: a 6-year multicentre experience. Europace 12(2): 181–187Google Scholar
  3. Cappato R, Calkins H, Chen S-A et al (2010) Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3(1):32–38PubMedGoogle Scholar
  4. Crandall MA, Bradley DJ, Packer DL et al (2009) Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc 84(7):643–662PubMedGoogle Scholar
  5. Demosthenes G, Katritsis A, Camm J (2010) Atrioventricular Nodal Reentrant Tachycardia Circulation 122:831–840Google Scholar
  6. Drew BJ, Ackerman MJ, Funk M et al (2010) On behalf of the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation Prevention of Torsade de Pointes in Hospital Settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 121:1047–1060PubMedGoogle Scholar
  7. El-Chami MF, Kilgo P, Thourani V et al (2010) New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol 55:1370–1376PubMedGoogle Scholar
  8. Jons C, Moss AJ, Goldenberg I et al (2010) Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol 55:783–788PubMedGoogle Scholar
  9. Kowey PR, Dorian P, Mitchell LB et al (2009) Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2:652–659PubMedGoogle Scholar
  10. Marcus FI, McKenna WJ, Sherrill D et al (2010) Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation [Epub ahead of print]Google Scholar
  11. Metzner A, Chun KRJ, Neven K et al (2010) Long-term clinical outcome following pulmonary vein isolation with high-intensity focused ultrasound balloon catheters in patients with paroxysmal atrial fibrillation. Europace 12(2):188–193PubMedGoogle Scholar
  12. Thermistoclakis S, Corrado A, Marchlinski FE et al (2010) The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 55:735–743Google Scholar
  13. Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298(11):1312–1322PubMedGoogle Scholar

Case Studies

  1. Amiodarone vs. Sotalol Study Group (1989) Multi-centre randomized trial of sotalol vs. amiodarone for chronic malignant ventricular tachyarrhythmias. Eur Heart J 10:685Google Scholar
  2. Belluzzi F, Sernesi L, Preti P et al (2009) Prevention of recurrent lone atrial fibrillation by the angiotensin-ii converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 53:24–29PubMedGoogle Scholar
  3. Burkhart F, Pfisterer M, Kiowski W et al (1990) Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 16:1711. BASISGoogle Scholar
  4. Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA Pilot Study Presented by Dr. Douglas Packer at the ACC.10/i2 Summit), Atlanta, GA, March 2010Google Scholar
  5. Connolly SJ, Ezekowitz MD, Yusuf S et al the RE-LY Steering Committee and Investigators (2009) Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151. RE-LYPubMedGoogle Scholar
  6. Hohnloser SH, Crijns HJGM, Eickels M et al for the ATHENA Investigators (2009). Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668–678. ATHENAPubMedGoogle Scholar
  7. Kober L, Torp-Pedersen C, McMurray JJV et al for the Dronedarone Study Group (2008) N Engl J Med 358:2678PubMedGoogle Scholar
  8. Mason JW on behalf of the ESVEM investigators (1993) A comparison of 7 anti-arrhythmic drugs in patients with ventricular tachyarrhythmia. N Engl J Med 329:452. ESVEMPubMedGoogle Scholar
  9. Opolski G, Torbicki A, Kosior DA et al (2004) Rate control vs. rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the polish how to treat chronic atrial fibrillation (HOT CAFE) Study. Chest 126:476–486. HOT CAFEPubMedGoogle Scholar
  10. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 22:1505Google Scholar
  11. Tuncer M, Fettser DV, Gunes Y et al (2008) Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hyper-tension (in Russian). Kardiologiia 48:42–45PubMedGoogle Scholar
  12. Van Gelder IC, Groenveld HF, Crijns HJGM et al for the RACE II Investigators (2010) Lenient versus strict rate control in patients with atrial fibrillation. Published at www.nejm.org March 15, 2010 (10.1056/NEJMoa1001337). RACEGoogle Scholar
  13. Wyse DG, Waldo AL, DiMarco JP et al for Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833. AFFIRMPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2011